Ribomic
Business Services · Japan · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Usui Bldg 3-16-13 Shirokanedai, Shirokan...Phone Number
+81 334403033Website
www.ribomic.comRevenue
<$5 MillionStock Symbol
4591Industry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Ribomic
株式会社リボミック specializes in developing drugs for untreatable diseases using aptamers. They utilize their proprietary drug discovery technology, the RiboART system, to create a variety of new drugs that are not limited to specific diseases or target proteins. Their services include drug development, clinical trials, and the development of separation agents, with a focus on conditions such as age-related macular degeneration and achondroplasia. The company aims to partner with alliances to enhance their drug discovery and development efforts.Explore more
Ribomic Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ribomic your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Ribomic recently announced quarterly report
Ribomic, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Ribomic has recently received funding, and reach out quickly before it becomes old news!
Check out if Ribomic is spiking on competitors!
Click to see if Ribomic had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Ribomic launches new products
Funding: Get notified immidiatlly once Ribomic has new funding data
Congratulate Masked Content for being promoted to Masked Content at Ribomic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Ribomic is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ribomic is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ribomic.
Ribomic Tech Stack
A closer look at the technologies used by Ribomic
Ribomic News & Media
RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort
TOKYO--(BUSINESS WIRE)--RIBOMIC, Inc. (TOKYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, has been conducting a Phase IIa clinical trial of umedaptanib pegol (anti-FGF2 aptamer) in pediatric patients (5-14 years old) with achondroplasia (ACH), and today announces that the administration of the low-dose (0.3 mg/kg) subcutaneous injection (once a week) group (cohort 1Note 1) has been completed and demonstrated a positive impact of the test drug on the patieRIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study
TOKYO--(BUSINESS WIRE)--RIBOMIC Inc. (TOKYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, today announced that 13 patients have been enrolled in an observational study 1 of umedaptanib pegol (anti-FGF2 aptamer) in pediatric patients (5-14 years old) with Achondroplasia in an early phase II study. A low-dose subcutaneous study (Cohort1 2) to evaluate the efficacy and safety of umedaptanib pegol in six patients who have completed the observational study is oAchondroplasia Treatment Drug Market to Register Positive Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Ascendis Pharma, QED Therapeutics (BridgeBio), Novartis, Sanofi, RIBOMIC
The achondroplasia market size shall grow during the forecast period (2023–2032) due to the launch of upcoming therapies and the increasing cases of achondroplasia. This achondroplasia market is expected to increase at a significant rate. LAS VEGAS, Jan. 9, 2024 /PRNewswire/ --...RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)
TOKYO--(BUSINESS WIRE)--RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that the Eye has published full results from the phase 1 (SUSHI) and phase 2 (TOFU/RAMEN/TEMPURA) trials evaluating the efficacy and safety of intravitreal umedaptanib pegol in nAMD1,2. TOFU is a randomized, double-masked study assessing the efficacy of intravitreal umedaptanib pegol monotherapy or in combination with Eylea®, compared to Eylea® monothe
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ribomic
Sign Up For FreeTo access detailed company insights
株式会社リボミック specializes in developing drugs for untreatable diseases using aptamers. They utilize their proprietary drug discovery technology, the RiboART system, to create a variety of new drugs that are not limited to specific diseases or target proteins. Their services include drug development, clinical trials, and the development of separation ag... Read More
